{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T08:19:33Z","timestamp":1786781973795,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"crossref","award":["PJT-168865"],"award-info":[{"award-number":["PJT-168865"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00415-023-12109-y","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T09:02:23Z","timestamp":1700298143000},"page":"2108-2113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Plasma GFAP and its association with disease severity in Huntington\u2019s disease"],"prefix":"10.1007","volume":"271","author":[{"given":"K\u00fcbra","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Alpaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chouinard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-1741","authenticated-orcid":false,"given":"Andr\u00e9a L.","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"issue":"1","key":"12109_CR1","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. Nat Rev Dis Prim 1(1):15005","journal-title":"Nat Rev Dis Prim"},{"issue":"11","key":"12109_CR2","first-page":"1638","volume":"66","author":"N Pavese","year":"2006","unstructured":"Pavese N, Gerhard A, Tai YF et al (2006) Microglial activation correlates with severity in Huntington disease. Clin PET Study 66(11):1638\u20131643","journal-title":"Clin PET Study"},{"issue":"Pt 7","key":"12109_CR3","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A et al (2007) Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain 130(Pt 7):1759\u20131766","journal-title":"Brain"},{"issue":"6","key":"12109_CR4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biomedicines10061432","volume":"10","author":"A Jurcau","year":"2022","unstructured":"Jurcau A (2022) Molecular pathophysiological mechanisms in Huntington\u2019s disease. Biomedicines 10(6):1432. https:\/\/doi.org\/10.3390\/biomedicines10061432","journal-title":"Biomedicines"},{"issue":"2","key":"12109_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","volume":"60","author":"E Sapp","year":"2001","unstructured":"Sapp E, Kegel K, Aronin N et al (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60(2):161\u2013172","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"12109_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40478-020-0880-6","volume":"8","author":"O Al-Dalahmah","year":"2020","unstructured":"Al-Dalahmah O, Sosunov AA, Shaik A et al (2020) Single-nucleus RNA-seq identifies Huntington disease astrocyte states. Acta Neuropathol Commun 8(1):19","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"12109_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109308","volume":"36","author":"A Benraiss","year":"2021","unstructured":"Benraiss A, Mariani JN, Osipovitch M et al (2021) Cell-intrinsic glial pathology is conserved across human and murine models of Huntington\u2019s disease. Cell Rep 36(1):109308","journal-title":"Cell Rep"},{"issue":"3","key":"12109_CR8","first-page":"487","volume":"28","author":"TE Wood","year":"2019","unstructured":"Wood TE, Barry J, Yang Z, Cepeda C, Levine MS, Gray M (2019) Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington\u2019s disease mouse model. Hum Mol Genet 28(3):487\u2013500","journal-title":"Hum Mol Genet"},{"key":"12109_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104710","volume":"94","author":"C Sampaio","year":"2023","unstructured":"Sampaio C, Wilkinson HA (2023) Facilitating Huntington\u2019s disease research: plasma neurofilament levels as a promising enrichment biomarker for HD-ISS stage 1. EBioMedicine 94:104710","journal-title":"EBioMedicine"},{"key":"12109_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.parkreldis.2021.04.017","volume":"87","author":"GM Parkin","year":"2021","unstructured":"Parkin GM, Corey-Bloom J, Snell C, Castleton J, Thomas EA (2021) Plasma neurofilament light in Huntington\u2019s disease: a marker for disease onset, but not symptom progression. Parkinsonism Relat Disord 87:32\u201338","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"12109_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A et al (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 78(12):1471\u20131483","journal-title":"JAMA Neurol"},{"issue":"2","key":"12109_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/biom12020222","volume":"12","author":"F Azzolini","year":"2022","unstructured":"Azzolini F, Gilio L, Pavone L et al (2022) Neuroinflammation is associated with GFAP and sTREM2 levels in multiple sclerosis. Biomolecules 12(2):222. https:\/\/doi.org\/10.3390\/biom12020222","journal-title":"Biomolecules"},{"issue":"7","key":"12109_CR13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S1474-4422(17)30117-5","volume":"16","author":"J van der Naalt","year":"2017","unstructured":"van der Naalt J, Timmerman ME, de Koning ME et al (2017) Early predictors of outcome after mild traumatic brain injury (UPFRONT): an observational cohort study. Lancet Neurol 16(7):532\u2013540","journal-title":"Lancet Neurol"},{"key":"12109_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.779890","volume":"12","author":"H You","year":"2021","unstructured":"You H, Wu T, Du G et al (2021) Evaluation of blood glial fibrillary acidic protein as a potential marker in Huntington\u2019s disease. Front Neurol 12:779890","journal-title":"Front Neurol"},{"issue":"11","key":"12109_CR15","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1007\/s00415-018-9022-5","volume":"265","author":"HL Denis","year":"2018","unstructured":"Denis HL, Lamontagne-Proulx J, St-Amour I et al (2018) Platelet-derived extracellular vesicles in Huntington\u2019s disease. J Neurol 265(11):2704\u20132712","journal-title":"J Neurol"},{"issue":"2","key":"12109_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00018-023-04687-x","volume":"80","author":"HL Denis","year":"2023","unstructured":"Denis HL, Alpaugh M, Alvarez CP et al (2023) Detection of antibodies against the huntingtin protein in human plasma. Cell Mol Life Sci 80(2):45","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"12109_CR17","first-page":"136","volume":"11","author":"Unified Huntington's Disease Rating Scale","year":"1996","unstructured":"Unified Huntington\u2019s Disease Rating Scale (1996) reliability and consistency. Huntington Study Group Mov Disord 11(2):136\u2013142","journal-title":"Huntington Study Group Mov Disord"},{"issue":"5","key":"12109_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ana.410410521","volume":"41","author":"JB Penney Jr","year":"1997","unstructured":"Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington\u2019s disease. Ann Neurol 41(5):689\u2013692","journal-title":"Ann Neurol"},{"issue":"10","key":"12109_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577\u2013589","journal-title":"Nat Rev Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12109-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-12109-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12109-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:06:57Z","timestamp":1711548417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-12109-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["12109"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-12109-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,18]]},"assertion":[{"value":"19 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}